Dr Reddys launches generic version of Tobi in US market
The product is a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).
Hyderabad: Dr Reddy's Laboratories Ltd. (Dr Reddys), along with its subsidiaries together referred to as "Dr Reddy's") recently announced the launch of Tobramycin Inhalation Solution, USP in the United States' market.
The product is a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA). Tobi is indicated for the management of cystic fibrosis
Also Read: Dr Reddys unveils generic version of Vitamin K1 injection in US
The TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.
Dr Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.
Tobi is a trademark of Mylan.
Also Read: Dr Reddys gets two USFDA observations for Vizag plants
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd